We invest in the development of exciting life science programs and the growth of current or future innovative market segment leaders.

TVM Capital Life Science was born out of venture capital firm Techno Venture Management, which was launched in 1983 and has focused exclusively on what we know best – Life Sciences – since 2012. TVM Capital Life Science has emerged as one of the leading international venture capital firms in the field.

TVM strategically refocused in 2012 to best exploit untapped industry potential. To achieve this, we adopted a dual-investment approach. This involves creating single-asset companies to bring early-stage therapeutics to clinical proof of concept, aided by a strategic partnership with global pharmaceutical company Eli Lilly and Company (Lilly). In addition, we invest in companies with commercial-stage medtech, diagnostics, and digital health and late-stage therapeutics with the potential to change standard of care.

TVM focuses on investing in assets and companies that provide a clear and attractive exit strategy from the outset, with the goal of maximizing returns in a reasonable timeframe.

However, we contribute more than just capital. TVM has a long history of providing portfolio companies with what each uniquely needs to succeed, including recruiting new management and board members, honing development, sales and marketing plans, QMS and manufacturing/supply chain logistics, regulatory strategies, finding potential partners and carrying out financing and exit strategies.

We are proud to have been instrumental in building groundbreaking companies that became industry leaders. Together with our partners, we are re-shaping modern medicine, bringing innovative therapeutics and medical technologies to patients in need.

Our team members have highly complementary skill sets paired with significant industry experience, ranging from former senior pharmaceutical industry executives, drug developers and deal makers to investment managers and corporate finance specialists. This multi-faceted expertise, combined with our extensive global network in research, product development and commercialization, enables us to bring a broad perspective to the table for building successful life science products and companies.